Primary Biliary Cholangitis (PBC) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight 1
DelveInsight Business Research LLP
DelveInsight’s ‘Primary Biliary Cholangitis – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

DelveInsight has launched a new report on “Primary Biliary Cholangitis (PBC) – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Primary Biliary Cholangitis (PBC) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Primary Biliary Cholangitis (PBC), historical and forecasted epidemiology as well as the  Primary Biliary Cholangitis (PBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. According to study, PBC affected individuals are usually in their fifth to seventh decades of life at time of diagnosis, and 90% are women. Annual incidence is estimated at between 1/1,430,000 and 1/20,400 inhabitants and prevalence at between 1/150,000 and 1/1,063 inhabitants (depending on age and sex).

  2. As per the study, point prevalence of Primary biliary cholangitis was calculated as 27.90 per 100,000 and incidence as 5.31 per 100,000 inhabitants/year. 

  3. As per one study, out of all the studied patients,approximately 7-11% of PBC patients were found to be males.

Key benefits of the report:

1. Primary Biliary Cholangitis (PBC) market report covers a descriptive overview and comprehensive insight of the Primary Biliary Cholangitis (PBC) epidemiology and Primary Biliary Cholangitis (PBC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Primary Biliary Cholangitis (PBC) market report provides insights on the current and emerging therapies.

3. Primary Biliary Cholangitis (PBC) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Primary Biliary Cholangitis (PBC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Primary Biliary Cholangitis (PBC) market.

Request for s ample pages: https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-market

Primary Biliary Cholangitis (PBC): Overview

Primary Biliary Cholangitis (PBC) is a chronic cholestatic disease with a progressive course that may extend over many decades. It is considered an autoimmune disease because of its hallmark serologic signature, antimitochondrial antibody (AMA), and specific bile duct pathology

The key players involved in the Primary Biliary Cholangitis (PBC) market:

  1. Enanta Pharmaceuticals

  2. Genfit

  3. Chia Tai Tianqing Pharmaceutical

  4. Cara Therapeutics

The launch of the emerging therapies is expected to significantly impact the Primary Biliary Cholangitis (PBC) treatment scenario in the upcoming years:-

Drug covered

  1. EDP-305

  2. Elafibranor

  3. TQA3526 

  4. CR845

Request a free sample report @https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Primary Biliary Cholangitis (PBC) Patient Share (%) Overview at a Glance

5. Primary Biliary Cholangitis (PBC) Market Overview at a Glance

6. Primary Biliary Cholangitis (PBC) Disease Background and Overview

7. Primary Biliary Cholangitis (PBC) Epidemiology and Patient Population

8. Country-Specific Patient Population of Primary Biliary Cholangitis (PBC)

9. Primary Biliary Cholangitis (PBC) Current Treatment and Medical Practices

10. Unmet Needs

11. Primary Biliary Cholangitis (PBC) Emerging Therapies

12. Primary Biliary Cholangitis (PBC) Market Outlook

13. Country-Wise Primary Biliary Cholangitis (PBC) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Primary Biliary Cholangitis (PBC) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Primary Biliary Cholangitis – Pipeline Insights, 2021

“Primary Biliary Cholangitis – Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Primary Biliary Cholangitis market. A detailed picture of the Primary Biliary Cholangitis pipeline landscape is provided, which includes the disease overview and Primary Biliary Cholangitis treatment guidelines.

Primary Biliary Cholangitis (PBC) -Epidemiology Forecast to 2030

DelveInsight’s ‘Primary Biliary Cholangitis- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Primary Biliary Cholangitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/